Fenofibrate [orch, phsu]
Review [inpr]
pharmacodynamic [biof]
properties [qlco]
Clinical [qlco]
Efficacy [qlco]
Management [ocac]
Dyslipidaemia [dsyn]
Fenofibrate [orch, phsu]
New [tmco]
Formulation [resa]
fibric acid [orch, phsu]
Derivative [ftcn]
Fenofibrate [orch, phsu]
Indicated [fndg]
treatment [ftcn]
Patients [podg]
Type [qlco]
III [inpr]
Dyslipidaemia [dsyn]
Failed [ftcn]
To [qlco]
dietary control [topp]
interventions [hlca]
Fenofibrate [orch, phsu]
Improved [qlco]
absorption characteristics [ftcn]
Compared [acty]
Standard Preparation [irda]
allowing [socb]
Lower [spco]
Daily [tmco]
Dosage [qnco]
Daily [tmco]
Administration [ocac]
Lipid [lipd]
MODIFY [ftcn]
Profile [lbpr]
Fenofibrate [orch, phsu]
Decrease [qlco]
Low density lipoprotein [aapp, bacs, lipd]
Total Cholesterol [lbpr]
Level [qlco]
Marked [qlco]
reduction [npop]
Elevated [qlco]
Plasma triglyceride level [lbpr]
Increase [ftcn]
High density lipoprotein cholesterol level [lbpr]
Consistent [idcn]
Standard [qlco]
Formulation [resa]
Administered [ftcn]
Daily [tmco]
divided [ftcn]
Dose [qnco]
Preparation [ftcn]
Efficacy [qlco]
treatment [ftcn]
Type [qlco]
Primary [qlco]
Dyslipidaemia [dsyn]
Lower [spco]
Daily [tmco]
Dosage [qnco]
Daily [tmco]
Triglyceride [bacs, lipd]
lowering [spco]
Effect [qlco]
Fenofibrate [orch, phsu]
APPEAR [qlco]
To [qlco]
Greatest [qnco]
Benefit [qnco]
Patients [podg]
Hypertriglyceridaemia [fndg]
Hypercholesterolaemia [dsyn]
Including [ftcn]
Patients [podg]
Diabetes Mellitus, Non-Insulin-Dependent [dsyn]
Dyslipidaemia [dsyn]
Comparison [acty]
Available [ftcn]
Fenofibrate [orch, phsu]
Daily [tmco]
Similar [qlco]
Efficacy [qlco]
effective [qlco]
HMG-CoA Reductase Inhibitors [orch, phsu]
Simvastatin [orch, phsu]
Daily [tmco]
Pravastatin [orch, phsu]
Daily [tmco]
Reducing [qlco]
Low density lipoprotein [aapp, bacs, lipd]
Total Cholesterol [lbpr]
Level [qlco]
Fenofibrate [orch, phsu]
Improvement [cnce]
Triglyceride [bacs, lipd]
High density lipoprotein cholesterol level [lbpr]
Simvastatin [orch, phsu]
Pravastatin [orch, phsu]
Data [idcn]
Long-term [tmco]
TOLERABILITY [resa]
Fenofibrate [orch, phsu]
Limited [ftcn]
Data [idcn]
Large [qnco]
Short-term [tmco]
month [tmco]
Study [mnob]
Indicated [fndg]
gastrointestinal disorders [dsyn]
Most [qnco]
Frequent [tmco]
adverse events [fndg]
Associated [qlco]
therapy [ftcn]
elevations [spco]
Serum [bdsu]
Transaminase [aapp, enzy]
creatine kinase levels [fndg]
Reported [inpr]
Rarely [qlco]
Fenofibrate [orch, phsu]
Conclusion [idcn]
Available [ftcn]
Data [idcn]
Suggest [idcn]
More [ftcn]
Lower [spco]
Daily [tmco]
Dosage [qnco]
Fenofibrate [orch, phsu]
Lipid [lipd]
MODIFY [ftcn]
effects [qlco]
Standard [qlco]
Formulation [resa]
Further [spco]
studies [lbpr]
Required [ftcn]
To [qlco]
Lipid [lipd]
Fenofibrate [orch, phsu]
Result [ftcn]
reduction [npop]
Cardiovascular morbidity [dsyn]
Mortality [qnco]
